Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Interim Results from Pivotal Phase 2 Portion of ZUMA-1 Clinical Trial of KTE-C19 Expected in September 2016

Source Link:: http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=983481

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

KITE

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "We have enrolled all 72 chemorefractory diffuse large B-cell lymphoma (DLBCL) patients in the pivotal portion of our ZUMA-1 study, and Kite remains on track to announce interim data from approximately 50 of these patients at 3-month follow-up later this quarter."

http://ir.kitepharma...

Additional Relevant Details "We remain on track to provide interim data from the pivotal phase 2 portion of the study later this year and to submit the KTE-C19 registration filing to the U.S. Food and Drug Administration (FDA) by the end of 2016."

http://ir.kitepharma...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Sep 26, 2016

Occurred Source:

http://ir.kitepharma.com/releasedetail.cfm?ReleaseID=990947

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Zuma-1, Zuma-1 Clinical Trial, Kte-c19